Drugstore Co., Ltd. (the “Company”) announces its annual results for the year ended 31 December 2023. The Group's revenue reached approximately RMB169.72 billion, an increase of 18.9% year-on-year. The revenue of self-employed business is about RMB160.36 billion, platform business revenue is RMB8.73 million, and other business income is RMB6291 million. Gross profit increased to approximately RMB17.41 billion, an increase of 21.3%. The year-on-year loss widened to approximately RMB 32.7 billion, an increase of 113.8% from the same period last year. Adjusted net profit was approximately RMB1.31 million under non-international financial reporting criteria. Total GMV reached RMB469.12 billion, up 24.0% year-on-year. The Company successfully entered the Hong Kong capital market in 2023 and continues to drive innovation and development in the out-of-hospital medical market to improve the efficiency of the industry. DURING THE REPORTING PERIOD, THE GROUP DID NOT DISTRIBUTE ANY DIVIDENDS.

Drugstore Co., Ltd. (the “Company”) announces its annual results for the year ended 31 December 2023. The Group's revenue reached approximately RMB169.72 billion, an increase of 18.9% year-on-year. The revenue of self-employed business is about RMB160.36 billion, platform business revenue is RMB8.73 million, and other business income is RMB6291 million. Gross profit increased to approximately RMB17.41 billion, an increase of 21.3%. The year-on-year loss widened to approximately RMB 32.7 billion, an increase of 113.8% from the same period last year. Adjusted net profit was approximately RMB1.31 million under non-international financial reporting criteria. Total GMV reached RMB469.12 billion, up 24.0% year-on-year. The Company successfully entered the Hong Kong capital market in 2023 and continues to drive innovation and development in the out-of-hospital medical market to improve the efficiency of the industry. DURING THE REPORTING PERIOD, THE GROUP DID NOT DISTRIBUTE ANY DIVIDENDS.